28.02.2011 • NewsNovartisGenoptix

Novartis to Make Second Offer for Genoptix Shares

Novartis said on Monday it would begin a second offer period for shares in U.S. cancer diagnostics company Genoptix after securing acceptances for 80% in the initial offer.

The holders of shares tendered in the second period, which closes on March 4, will be paid $25 per share, the same amount offered in the initial offer period, the Swiss drugmaker said.

Independent analysts had placed the stock's value as high as $28.00 per share, legal advisers The Briscoe Law Firm PLLC and Powers Taylor LLP, said in January, when the deal was first announced.

Genoptix, a laboratory specialising in diagnosing cancers in bone marrow, blood and lymph nodes, had sales of $184 million in 2009 and employs 500 staff, Novartis said in January.

Novartis wrapped up its $52 billion buyout of U.S. eyecare group Alcon last year after a protracted battle with the U.S.-listed company's minority shareholders. Novartis shareholders will vote on that merger and on a proposed capital increase at an extraordinary meeting on April 8.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.